Key study for central precocious puberty shows continued support from DSMB.
- Foresee Pharmaceuticals receives fourth DSMB recommendation.
- CASPPIAN study focuses on central precocious puberty.
- Study progress supports further clinical developments.
Foresee Pharmaceuticals has announced that it received a fourth positive recommendation from the Data and Safety Monitoring Board (DSMB) regarding the CASPPIAN Phase 3 study. This clinical trial is aimed at evaluating the efficacy and safety of a treatment for central precocious puberty (CPP). This recommendation allows the company to continue its investigation into the treatment's impact on this condition.
The DSMB's ongoing support highlights the study's progress and the safety profile observed so far. Central precocious puberty is a condition characterized by the onset of secondary sexual characteristics before age 9 in boys and before age 8 in girls. The CASPPIAN study continues to play a crucial role in understanding potential treatments for this condition.
Each recommendation from the DSMB reflects the board's evaluation of the data gathered throughout the trial, ensuring participant safety and study integrity. Foresee Pharmaceuticals remains committed to advancing research in this area, as demonstrated by its dedication to the CASPPIAN study.
